Gratzke C, Chapple C, Mueller ER, et al. - A literature search was done in June 2018 by the researchers in order to assess the efficiency and safety of combination therapy in patients with overactive bladder (OAB). Combination therapy was non-inferior to solifenacin 10 mg (S10) for the decline in urinary incontinence (UI) and for improvement in micturition frequency, it was better to S10 and led to higher improvements from baseline in OAB-5 Dimension scores vs S5 and S10. For M50 + S5 vs M50 or S5, in SYNERGY II, clinically significant and sustained improvements in clinical outcomes were noted. In all four trials, combination therapy was well tolerated. The incidence of adverse events (AEs) was comparable among groups, and no striking variations in the incidence of specific AEs were observed. In five studies of dual antimuscarinic therapy (trospium + solifenacin), positive efficiency outcomes were recognized. In conclusion, for patients with OAB, mirabegron plus solifenacin gave efficient, well-tolerated treatment. Insufficient data for dual antimuscarinic therapy recommended an advantage in patients with moderate-to-severe symptoms.